Insights From the FAST-TRACK CABG Trial: a Clinical Outcome Study in Patient With Previous
Coronary computed tomography angiography (CCTA) is a non-invasive imaging tool that characterizes coronary artery anatomy and provides detailed assessments of plaque morphology, composition , inflammation, and hemodynamics, which have crucial prognostic implications. The FASTTRACK CABG trial demonstrated that CCTA- fra
| Condition(s) | Multivessel Coronary Artery Disease |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Coronary computed tomography angiography (CCTA) is a non-invasive imaging tool that characterizes coronary artery anatomy and provides detailed assessments of plaque morphology, composition , inflammation, and hemodynamics, which have crucial prognostic implications. The FASTTRACK CABG trial demonstrated that CCTA- fractional flow reserve derived from CCTA can plan and guide coronary artery bypass grafting treatment without traditional invasive coronary angiography and provides a valuable dataset of pre- and post-CABG CCTA for further research. This study is a sub-analysis of the FASTTRACK CABG trial and aims first of all to assess whether these imaging-derived markers can predict symptomatic relief and clinical outcomes for patients undergoing CABG, for complex three-vessel or left main c |
| Who can participate | Inclusion Criteria: * Patients who have analyzable pre-CABG CCTA imaging and received a successful CCTA-guided plus FFRCT CABG procedure. * Patient with known level of Lp(a) or with possibility to perform the test * Patent able to provide written informed consent as approved by the Ethical Committee Exclusion Criteria: * Patients without pre-CABG CCTA imaging or those with who did not receive surgical revascularization. * Current treatment with lipoprotein apheresis * Patients who refuse to receive clinical follow-up * Unable to give Informed Consent |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Centro Cardiologico Monzino |
| Locations | Milan, MI, Italy |
| Start date | 2025-09-01 |
| NCT ID | NCT07628270 |
| Official listing | https://clinicaltrials.gov/study/NCT07628270 |